DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Axial Spondyloarthritis - Pipeline Review, H1 2016" report to their offering.
The report provides comprehensive information on the therapeutics under development for Axial Spondyloarthritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Axial Spondyloarthritis and features dormant and discontinued projects.
The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
- The report provides a snapshot of the global therapeutic landscape of Axial Spondyloarthritis
- The report reviews pipeline therapeutics for Axial Spondyloarthritis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report reviews key players involved Axial Spondyloarthritis therapeutics and enlists all their major and minor projects
- The report assesses Axial Spondyloarthritis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- AbbVie Inc.
- Eli Lilly and Company
- Johnson & Johnson
- Novartis AG
- Sandoz International GmbH
- UCB S.A.
- Xbrane Biopharma AB
For more information visit http://www.researchandmarkets.com/research/2nhvqz/axial